Journal of Diabetes and its Complications · 2023 · 13 citations · 17 references
Life SciencesImmunologyPharmacologyCell SignalingInflammationSignal TransductionAntifibrotic TherapyHepatic FibrosisHepatic PathophysiologyInflammatory SignalingLiver DiseaseMetabolic InflammationHepatocellular Carcinoma PathogenesisInflammation In Liver InjuryInflammatory CascadeInflammatory Liver InjuryLiver Fibrosis ProgressionLiver Inflammation SignalingNonalcoholic Steatohepatitis Associated Fibrosis
Non-alcoholic fatty liver disease (NAFLD) is increasing globally, and seeking therapeutic molecule targets is urgent. Several studies have demonstrated that IL-33 plays an important role in the progression of Non-alcoholic steatohepatitis (NASH) with fibrosis and the proliferation of hepatocellular carcinoma (HCC). However, whether the inhibition of IL-33 signaling prevents NAFLD from progressing to NASH and HCC has not been clarified. We investigated the effects of a novel antibody, IL-33RAb, and luseogliflozin, a SGLT2 inhibitor, when administered to a model mouse for NASH and HCC, and their effects were compared to investigate the mechanisms of how IL-33 is involved in the pathogenesis of NASH progression. Compared with the positive control of luseogliflozin, inhibition of IL-33 signaling ameliorated decreasing hepatic fibrosis via decreasingαSMA and MCP-1, and also partially suppressed the progression of the HCC cell line in in vitro experiments. These findings suggest that inhibition of IL-33 possibly prevents progression from NASH to HCC, and their effect may be a newly arrived therapeutic agent.
17
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations
CCR2 promotes hepatic fibrosis in mice #
Ekihiro Seki, Samuele De Minicis, Sayaka Inokuchi et al. · Hepatology · 2009 · 412 citations